Moderna Stock: Speculations Regarding the Company’s Stock

Moderna stock boosted after it announced its vaccine and after this, it was expected that the company’s stock would perform well. However, things did not go as smoothly as expected and the stock fluctuated a lot. The company’s stock faced ups and downs lately and this has made the decision of investing in Moderna stock quite speculative. Moderna’s vaccine got approved by the Food and Drug Administration (FDA). It was developed and formulated using the messenger RNA (mRNA) technology and in this matter, the vaccine shares its similarity with the vaccine that Pfizer developed with its partner BioNTech and got it approved. Moderna Inc. (NASDAQ: MRNA) Moderna has claimed that its vaccine is 94.1% effective against the infection of the novel coronavirus. The vaccine has got approval and authorization in various countries around the world (more than 30). The company is making more and more doses of the vaccine as per the requirement of the same. 1.4 billion doses of this vaccine are expected in this year 2021 and could be more depending upon the demand of the vaccine. The final quarter revenue of Moderna has come out to be $571 million (in 2019, the fourth-quarter revenue was $14 million). The total annual revenue for the year 2020 was $803 million. Moderna’s Latest Report on Statistics 52 Week Range: $19.31 - $189.26 Average Volume: 18,759,237 Market Capital: $52.458B Forward Dividend and Yield: N/A (N/A) When is the Right Time to Invest in Moderna Stock? Moderna has not had a very…

AbbVie Stock: Safe to buy or not?

AbbVie Inc. (NYSE: ABBV) is a relatively new biopharmaceutical company of the United States and its foundation was laid in the year 2013. The company has had fairly well performance and has given profits to the shareholders who have invested in this firm. The company is doing well and is going at a steady pace. The stock of this company comes with a dividend. The investors have to figure out between the dividend stocks since these are associated with the risk of increment or decrement of the dividend with time. An increase of dividend is always welcome while a reduction of the dividend brings loss in the investment. AbbVie Inc. (NYSE: ABBV) Stock analysis  52 Week Range: $62.55 - $113.41 Average Volume: 8,361,700 Market Capital: $197.326B Forward Dividend and Yield: 20 (4.71%) The pricing of the stock is moderate and the dividend is also high. The dividend has shown an increase and therefore, the stock becomes a less risky dividend stock with a higher probability of returning profits to the investors. AbbVie and Humira: What’s in for the Future? Humira being the consistently best-selling drug of the company overshadows the other products sometimes but now the other drugs, which are also highly effective against the respective diseases they are used to treat. Humira is however a very important drug and it is not sure whether a new drug can replace this drug because it is highly reliable. This doubt is there in the minds of the investors. If we consider…